TTK Healthcare Stock Jumps Nearly 4% Despite FY26 PAT Falling 20%

Synopsis: Reporting audited results for the fourth quarter and full year ended March 31, 2026, TTK Healthcare posted a 20 percent decline in full-year net profit, weighed by the absence of a property sale gain booked in FY25 and a one-off labour code liability charge; the board has recommended a dividend of Rs. 10 per share, and the stock has lost roughly 32 percent over the past year.

A Chennai-headquartered diversified healthcare and consumer products company came into focus on May 30, 2026, after its board approved audited results for FY26 and declared a final dividend. The filing, submitted under Regulation 33 of SEBI (LODR) Regulations, 2015, reveals a year in which reported profit contracted sharply, though the drop is largely explained by two items that distort the headline comparison.

With a market capitalization of approximately Rs. 1,302 crore, the shares of TTK Healthcare Limited were last quoted at Rs. 922.4 per share, up 3.43 percent from its previous close of Rs.891.85. The stock is trading at a P/E of 19.19.

Full-Year Results Update

Revenue from operations for FY26 came in at Rs. 857.28 crore, up 7 percent from Rs. 801.49 crore in FY25, a steady, if unspectacular, topline. The operating picture looks softer, though: profit before finance costs, depreciation, exceptional items, and tax fell from Rs. 106.08 crore to Rs. 98.33 crore, implying a modest compression in operating profitability.

The headline PAT for FY26 stands at Rs. 65.68 crore, down from Rs. 81.66 crore in FY25  a 20 percent decline. That comparison, however, needs context. FY25 benefited from an exceptional gain of Rs. 19.77 crore (net) on the sale of leasehold land at Mahindra World City, Chennai. FY26, by contrast, carries a net exceptional charge of Rs. 4.07 crore, comprising a Rs. 7.58 crore one-time hit from the labour code reclassification (gratuity and compensated absences, triggered by the government’s notification of the four Labour Codes in November 2025), partially offset by a Rs. 3.50 crore GST refund received in Q4.

Strip both years of exceptional items, and the year-on-year PAT decline is still real pre-exceptional profit before tax fell from Rs. 94.43 crore to Rs. 86.64 crore  but the erosion is more moderate than the headline implies.

Segment Performance

The Protective Devices segment  which manufactures male contraceptives  remained troubled. FY26 segment profit was Rs. 2.53 crore, against Rs. 6.32 crore in FY25, and Q4 alone posted a segment loss of Rs. 1.10 crore. This segment had booked a Rs. 5.86 crore inventory write-off in Q4 FY25 due to cancellation of USAID purchase orders; the current year shows the division has not yet found its footing.

Medical Devices was a partial bright spot, with full-year segment profit at Rs. 22.54 crore, up marginally from Rs. 22.15 crore. The Animal Welfare segment grew revenue to Rs. 141.08 crore from Rs. 126.37 crore. Consumer Products and Foods also grew topline, though Consumer Products saw a profit pullback from Rs. 23.45 crore to Rs. 18.35 crore.

The company’s balance sheet remains unencumbered: total liabilities of Rs. 213.89 crore sit against total assets of Rs. 1,328.74 crore. Cash and bank balances (including fixed deposits) were substantial at roughly Rs. 633 crore, a feature that also explains the Rs. 72.15 crore in other income, almost entirely interest earnings on surplus funds. The Screener note flagging “other income of Rs. 59.6 crore” in trailing numbers is relevant: reported PAT is materially propped up by treasury income rather than operational performance, and with operating margins running at 3 to 4 percent, that pattern bears watching.

Corporate Actions and Board Changes

The board has recommended a final dividend of Rs. 10 per share (100 percent of face value) for FY26, subject to shareholder approval at the 68th AGM scheduled for July 24, 2026. At FY26 PAT of Rs. 65.68 crore, the total dividend payout of Rs. 14.13 crore represents a payout ratio of around 22 percent  unchanged from FY24 and broadly consistent with the company’s historical range, well within earnings.

The board also approved the re-appointment of Mr. T. T. Raghunathan as Executive Chairman for a further five-year term beginning November 1, 2026. A commerce graduate and chairman of the TTK Group, he has been on the board since 1998. 

Business Overview

TTK Healthcare Limited, incorporated in 1958 and listed on both BSE (507747) and NSE (TTKHLTCARE), operates across six business segments: Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, and a small publishing/maps division. The company is part of the T. T. Krishnamachari group, whose flagship is TTK Prestige.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post TTK Healthcare Stock Jumps Nearly 4% Despite FY26 PAT Falling 20% appeared first on Trade Brains.